Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Friday
Sep 03rd
Home arrow Farmavita.Net Journal arrow Diabetes Care Devices Market
Diabetes Care Devices Market Print E-mail
Business Reports - Market Report

gbi.jpg

The Future of the Diabetes Care Devices Market to 2016 - The Key Demand Drivers Remain Intact

GBI Research's new report, "The Future of the Diabetes Care Devices Market to 2016 - The Key Demand Drivers Remain Intact" provides key data, information and analysis on the global diabetes care devices market. The report provides market landscape, competitive landscape and market trends information on two diabetes care devices market categories - glucose monitoring and insulin delivery. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

The Global Diabetes Care Devices Market to Reach $18 Billion in 2016

The global diabetes care devices market was valued at $10.9 billion in 2009. Increasing affordability coupled with efforts to raise awareness towards better diabetes care management has resulted in rapid market penetration of products in the last seven years. The market is expected to continue with an increased growth over the next seven years to reach $18 billion in 2016 with a forecast Compounded Annual Growth Rate (CAGR) of 10% during 2009 - 2016. Increasing incidence of diabetes and the increase in affordability of devices for patients in developing nations will drive this growth.

Diabetes a Burden on Healthcare Spending

Diabetes in the US alone cost an estimated $174 billion in 2007. That is an increase of 32% since 2002, and it means that one in five dollars of the national healthcare spend is spent on someone who has been diagnosed with diabetes. This figure is expected to double over the next two decades. A recent study published by Novo Nordisk, has found that $60 billion, which is three-quarters of the US federal money spent on treating people with diabetes in 2005, came from Medicare, the US federal program for the poor and elderly.
Key opinion leaders suggest that the market for diabetes care devices in developing countries such as India, China and Brazil is huge. However, opinion leaders also state that low priced devices for diabetes care are still lacking in these markets. Manufacturers need to identify such markets and work towards devices that effectively cater to people with low affordability.

Reimbursement Issues For New Glucose Monitoring and Insulin Delivery Technologies Restraining the Market

The availability of reimbursement is a strong driver for any medical device market. Reimbursement increases affordability for the patient resulting in increase of revenues for the manufacturer.
Although most government and private health insurance providers allow reimbursement for diabetes care devices it has been slightly inadequate for new innovations such as the Continuous Glucose Monitors (CGM). While Medicare in the US includes reimbursement for glucose monitoring strips and meters, continuous glucose monitors and insulin delivery devices like injectors, pumps, reimbursement remains on a case by case basis for the CGM. Currently Medicare and other policies that do not reimburse CGM and assert that continuous monitoring of glucose levels in the interstitial fluid does not meet the Technology Evaluation Centers' (TEC) criteria for reimbursement. Insurance companies such as WellPoint, on the other hand, do provide insurance for CGM.

Disposable Insulin Pumps to Increase Acceptance of Insulin Pumps

The disposable insulin pump market in the US was valued at $31m in 2009. Driven by high acceptance of new technologies in the US and the pumps disposable nature, offering better quality of life, the market witnessed a CAGR of 33% from its inception in 2005 until 2009.

For further details, please click here. Reference Code: GBIME0001MR

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Comments
Search RSS
Only registered users can write comments!

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

Read also at Pharmaceutical Licensing Network
Related News
Related Items
Farmavita.Net - The Pharmaceutical Licensing Network




Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Blogmarks!Yahoo!Ma.gnolia!FeedMeLinks!Free social bookmarking plugins and extensions for Joomla! websites!
 
< Prev   Next >
Advertisement
 

Featured Partners

2010_pharmaci_banner_150x150.gif
jfbals88_banner_150x150_2.gif
bals89_150x150.gif
150x150_g-2.gif 
  dbls02_150x150banner.gif
150x150.gif
evolution_2010_150x150.gif
150x150_chronic10_master.gif
150x150_riskshna10_master.gif
dbls03_150x150_anim.gif
banner150_pm2010.gif
bals91_150x150_anim.gif

Login to Farmavita.Net

membership is FREE

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 63 guests and 1 member online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

bals90_150x150_anim.gif  

Reports

rbhc0264_privatehealthcare.gif 

Events

  chc197_150x150.gif

REPORTS

farmavita_research-store.gif